Role of Central Nervous System in the Progression of Preeclampsia
Abdoulaye Issotina Zibrila,Zheng Wang,Yuyao Sun,Gongxiao Zhao,Kaiyue Feng,Ying Ma,Leilei He,Yuejin Liang,Lynn Soong,Jinjun Liu
DOI: https://doi.org/10.1016/j.yjmcc.2019.11.141
IF: 5.763
2020-01-01
Journal of Molecular and Cellular Cardiology
Abstract:Preeclampsia (PE) is one of the most important human pregnancy complications, for which the pathophysiology is poorly defined. There are no validated and consensual animal models that resemble disease process in women; the mechanism underlying the increasing cardiovascular diseases (CVD) risk in mother and offspring by PE remains unclear. The aim of this study is to establish and characterize a Reduced Uterine Perfusion Pressure (RUPP) model in rats with characteristic features of PE and to use it for therapeutical trial and offspring health programming study. For this purpose, pregnant SD rats underwent a placental ischemia induction, based on timing and positional ligation of vessels. After RUPP operation, mean arterial pressure and proteinuria significantly increased. At the same time, the levels of glutamate, proinflammatory cytokines, phosphorylated IKKβ, nuclear factor-kappa B (NF-κB) activity, Fra-LI (an indicator of chronic neuronal activation), superoxide, gp91phox, Ang II, AT1, and ACE(angiotensin converting enzyme) were significantly increased in hypothalamic paraventricularnucleus (PVN). Pyridostigmine, a reversible cholinesterase inhibitor, treatment attenuated hypertension, and proteinuria and significantly reduced cytokine, NF-κBp65 activity, reactive oxygen species levels, and altered renin-angiotensin system components in the PVN of RUPP rats. Our findings suggest that PE increases NF-κB activity, proinflammatory cytokine levels, and oxidative stress, inducing an imbalance between excitatory and inhibitory neurotransmitters in the PVN. PYR treatment attenuates BP and proteinuria by attenuating oxidative stress and modulating the balance of the autonomic nerve system and renin-angiotensin system in the hypothalamic paraventricularnucleus.